Monitor the outcome of the Nasdaq hearing scheduled for May 5, 2026, as continued listing compliance remains uncertain despite previous recoveries.
Executive Summary
HCW Biologics Inc. is conducting an IPO amendment to raise up to $5.6 million through the issuance of common stock or pre-funded warrants. The company is a clinical-stage biopharmaceutical firm focused on developing fusion immunotherapeutics for chronic inflammation-related diseases. The offering proceeds will fund clinical trials, R&D, and general corporate purposes. The company faces Nasdaq compliance issues due to a low stock price and has a history of related-party financings.
Key Financial Metrics
Key Facts
- Company is a clinical-stage biopharmaceutical firm developing fusion immunotherapeutics for chronic inflammation-related diseases
- Raising up to $5.6 million through issuance of common stock or pre-funded warrants
- Proceeds will fund clinical trials, R&D, and general corporate purposes
- Company faces Nasdaq compliance issues due to low stock price
- History of related-party financings
Financial Impact
Up to $5.6 million in gross proceeds from the offering
Risk Factors
- Nasdaq listing compliance risk due to minimum bid price requirement
- Dilution to existing shareholders from the offering
- Dependence on related-party financings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001493152-26-018992 |
| Document: 0001493152-26-018992-index-headers.html | 0001493152-26-018992 |
| Document: 0001493152-26-018992-index.html | 0001493152-26-018992 |
| Document: 0001493152-26-018992.txt | 0001493152-26-018992 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | EFFECT | $1.26 | awaiting T+60 | — | $1.15 (+8.73%) |
Oct 2, 2026 24d ago | S-1 | $1.64 | awaiting T+60 | — | $1.15 (+29.88%) |
Oct 1, 2026 26d ago | DEF 14A | $1.69 | awaiting T+60 | — | $1.15 (+31.95%) |
Sep 24, 2026 4w ago | 8-K | $1.99 | awaiting T+60 | — | $1.15 (+42.21%) |
Aug 20, 2026 9w ago | S-1 | $2.12 | awaiting T+60 | — | $1.15 (−45.75%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.15 (+57.09%) |
Aug 14, 2026 10w ago | Press Release | $2.68 | awaiting T+60 | — | $1.15 (+57.09%) |
Aug 14, 2026 10w ago | 10-Q/A | $2.68 | awaiting T+60 | — | $1.15 (+57.09%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.15 (+57.09%) |
Jul 29, 2026 12w ago | Press Release | $2.58 $1.12 | ▲ +56.59% | ▲ +61.32% | $1.15 (+55.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers